Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Lymphoma 1

Interventions

pembrolizumab 24Paclitaxel 11Carboplatin 11Trastuzumab 9Nivolumab 7Fulvestrant 6palbociclib 4olaparib 4Taxes 4Surveys and Questionnaires 4Methods 4Early Intervention, Educational 4Docetaxel 4Cyclophosphamide 4Biopsy 4Bevacizumab 4pertuzumab 3lenvatinib 3fludarabine 3atezolizumab 3abemaciclib 3Tamoxifen 3Specimen Handling 3Psychiatric Rehabilitation 3Metformin 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Interviews as Topic 3Gemcitabine 3Counseling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × GSK2141795 × Breast × Clear all
NCT00920257 2017-11-13

A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

GlaxoSmithKline

Phase 1 Completed
77 enrolled
BreastGynecologicLymphoid

Breast Neoplasms, Lymphoma, Neoplasms, Endometrial Neoplasms

NCT01138085 2017-11-13

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

GlaxoSmithKline

Phase 1 Completed
240 enrolled
BreastGynecologic

Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡